eduKate Singapore

VIEW THIS AS

Auto mode follows the Route Engine until you choose a viewpoint.

YOU ARE HERE

ROUTE CHECK

CONNECTED TO

WHAT NEXT

Use the canonical route for this room, or HELP if you are unsure.

Next useful routeCanonical hubHELP

The Gold Standard of Health Economics

—

by

eduKate Asia

A new health programme produces a measurable benefit and costs more than existing care. Supporters call it invaluable; critics call it expensive. Neither description answers the first economic question: what health benefits, access and financial protection would be gained, and what alternative could the same limited resources provide? Health economics brings those trade-offs into the open without pretending a human life is reducible to a price.

The gold standard of health economics is a defensible comparison of choices. It connects patient needs, health-system incentives, cost definitions, outcomes, uncertainty, feasibility and equity to the actual decision-maker. This article works from first principles through eighteen chapters, two original calculations, frequent questions and a connected eduKate library.

This guide belongs to The Gold Standard. The term refers to reliable analysis and educational quality, not approval by WHO, NICE, ISPOR or any health payer, and not a recommendation for an individual patient’s treatment.

Quick information: what trustworthy health economics checks

  • Name the patient group, decision-maker, interventions and real comparator.
  • State which resources and health outcomes are valued and why.
  • Keep clinical effects, QALYs, prices, budget impact and equity distinct.
  • Show incremental arithmetic and assumptions rather than only a favourable ratio.
  • Test uncertainty, implementation capacity and distribution of benefits.
  • Follow current reporting guidance without assuming a UK rule applies worldwide.

Chapter index

1. Begin with the opportunity cost of every health decision

Back to contents

Health economics studies how people and institutions allocate limited resources to protect and improve health. A government, hospital, insurer or family cannot spend the same constrained resource twice. The opportunity cost of one decision is the best alternative benefit forgone, not merely a price shown on an invoice.

The gold standard is a comparison that explains what people gain, what resources are used, whose perspective counts and which alternative is displaced. This is not an argument that health should be treated as a commodity. It is a method for exposing trade-offs that can otherwise remain hidden behind a compelling story or a single impressive success.

2. Separate health needs, demand and measurable access

Back to contents

The need for care and the demand expressed through visits or purchases are not identical. People may need a service yet be unable to afford it, reach it, understand it or obtain an appointment. Recorded utilisation can underestimate unmet need. Conversely, extra visits do not automatically mean better health outcomes.

Investigate barriers, geographic access, eligibility, price paid, waiting time and other constraints. A system that lowers fees without adequate staffing might shift the bottleneck into queues. Judge performance by relevant coverage, quality and health effects, not only the number of encounters billed.

3. Understand uncertainty, insurance and pooling

Back to contents

Illness and treatment costs are uncertain for individuals, creating a reason to pool financial risk across groups. Health insurance and public financing can spread the cost of large unpredictable events. But financing design changes who pays, what is covered and when care is used.

Distinguish premiums, contributions, taxes, deductibles, co-payments and out-of-pocket charges. An average reimbursement figure does not reveal whether a low-income household faces catastrophic expense. Good economic analysis considers risk protection and fairness alongside use of resources.

4. Account for asymmetric information and trust

Back to contents

Patients often rely on clinicians for specialised information that they cannot easily verify. Providers and insurers may also hold different information about needs, costs, quality and risk. These asymmetries can affect choice, contracting, enrolment and incentives.

Economic concepts such as adverse selection and moral hazard can help analyse some situations, but they are not moral judgments about people seeking care. Ask what each participant knows, what choices are available and whether a proposed rule creates unintended barriers or incentives for low-value treatment. Ethical and clinical context remain essential.

5. Examine incentives for clinicians, hospitals and payers

Back to contents

Fee-for-service, salaries, bundled payments and capitation can encourage different provider behaviours. Each approach may solve one problem while creating another. For example, payment linked only to service volume might reward unnecessary activity, while a fixed budget without quality controls may underprovide care.

Specify the intended outcome and how quality, case complexity and vulnerable populations will be protected. Compare observed outcomes and avoid assuming a financial incentive determines every clinician’s behaviour. A good payment design needs clinical governance and transparent monitoring, not a spreadsheet alone.

6. Define the exact decision problem and comparator

Back to contents

Health economic evaluations compare alternatives. The relevant question may be whether to add a new screening programme, change a medicine, expand nursing services or redesign a discharge process. The comparator should reflect actual care or a feasible alternative, not an artificially weak option.

Define the population, setting, current practice, available alternatives and decision authority. A technology may look excellent against no service yet offer little advantage over an existing effective service. NICE’s technology-appraisal manual, updated in March 2026, formalises a reference-case approach to making assumptions and comparisons visible for its jurisdiction.

7. State whose costs and outcomes are counted

Back to contents

Perspective controls the answer. A hospital may consider staffing and equipment costs, a public payer may count covered services and a societal analysis may also assess patient time, travel, unpaid care or productivity. These are not automatically interchangeable totals.

Choose a perspective before collecting numbers and provide additional views separately when useful. Do not add costs from several payers without accounting for transfers and double counting. Explain whether the measured consequence is clinical health, financial protection, caregiver wellbeing or a wider social effect.

8. Measure resources before attaching prices

Back to contents

A cost study needs quantities of resources as well as unit prices: staff time, consumables, equipment, bed days, laboratory tests, follow-up and support services. Charges, reimbursements, listed prices and actual opportunity costs can differ. A lower purchase price may coincide with larger costs elsewhere in the service pathway.

Record the valuation date, currency, quantities, price sources and assumptions. One-off implementation costs and recurring operating costs belong in different periods. Understaffed capacity cannot be treated as an unlimited free resource simply because it already appears in a hospital budget.

9. Distinguish clinical effects from economic measures

Back to contents

A new service may change survival, symptoms, disability, disease detection, caregiver burden or quality of life. An economic conclusion depends on credible evidence about these outcomes. A higher number of tests performed is an activity measure, not automatically a health benefit.

Specify follow-up time, outcome definition and data quality. Randomised trials, observational evidence and models each have distinct inferential limits. Extrapolation beyond observed follow-up should be transparently justified and examined for sensitivity, rather than assuming short-term improvement continues forever.

10. Understand QALYs without reducing people to one number

Back to contents

A quality-adjusted life year combines duration with a health-related quality weight under an explicitly defined method. Under a simple constant-weight illustration, one year in a state with a utility weight of 0.8 corresponds to 0.8 QALYs. Real analyses may involve changing states, discounting, uncertainty and validated quality-of-life instruments.

QALYs support comparisons across unlike interventions, but they are not a complete measurement of dignity, equity, identity or social participation. Health-state valuation is contested in some contexts and can miss outcomes important to particular communities. Report the instruments, weights and value judgments as part of the evidence, not as invisible facts.

11. Compare incremental costs with incremental benefits

Back to contents

An incremental cost-effectiveness ratio (ICER) compares the additional expected cost of an intervention with the additional expected health benefit relative to a stated comparator. In a cost-utility evaluation, that benefit is often measured in QALYs. The arithmetic is meaningful only when costs and benefits have aligned populations, periods and perspectives.

An intervention that costs more and improves health may present a trade-off; one that costs less and improves health is economically dominant in the simple comparison. A ratio should not be computed mechanically when the outcome difference is zero or when doing so obscures dominance. Present absolute values and incremental differences so a reader can reconstruct the conclusion.

12. Use decision thresholds in their actual setting

Back to contents

A cost-effectiveness threshold represents a decision context’s interpretation of value or opportunity cost. It is not a universal law of nature or an exchange rate for human wellbeing. Policies, budget constraints, equity modifiers and evidence requirements differ by jurisdiction and may change.

NICE’s current technology-appraisal methods, updated 31 March 2026, discuss incremental analysis and contemporary UK reference-case thresholds, including net-health-benefit illustrations. Those values should not be imported into Singapore, another country or a fictional example as automatic approval rules. State the authority, date, programme and decision process to which any threshold belongs.

13. Keep budget impact distinct from cost-effectiveness

Back to contents

A programme can be cost-effective in the long term yet unaffordable within this year’s cash budget. Budget impact analysis estimates likely financial effects under assumptions about eligible people, uptake, pricing, substitution, timing and service capacity. It is a companion to, not a replacement for, economic value assessment.

Do not apply a per-patient estimate to an entire population without modelling actual uptake and implementation. Some costs are up-front, while benefits or savings arise later or outside the payer’s budget. Report timing and uncertainty; a favourable lifetime ICER does not mean a payer has the cash needed for full launch tomorrow.

14. Discount future costs and outcomes transparently

Back to contents

In evaluations extending across years, future costs and health effects may be discounted to a reference time under the relevant methodology. The rate, timing convention and rationale can materially change long-horizon results, especially for prevention or treatments with durable outcomes.

NICE’s updated 2026 reference case specifies 3.5% per year for costs and effects, with certain circumstances for alternate analyses. Other settings may require different approaches. A toy calculation of one unit realised two years later at 3.5% has present value 1 ÷ 1.035², approximately 0.933 units. This arithmetic does not determine which discount rate a jurisdiction ought to use.

15. Expose parameter, structural and population uncertainty

Back to contents

Costs, event rates, quality weights, adherence and long-term treatment effects are estimated with uncertainty. Sensitivity analysis explores how results change when plausible inputs vary. Model structural choices, such as a health-state layout or extrapolation curve, may have different consequences from statistical uncertainty in one parameter.

Present deterministic scenarios and, where appropriate, probabilistic analysis with justified distributions and correlation assumptions. Show which uncertain parameter might reverse the decision. A narrow confidence interval from an oversimplified model does not establish that the underlying health system has been adequately represented.

16. Test equity, distribution and feasibility

Back to contents

A programme may generate substantial aggregate health gains while benefiting mainly well-served groups or leaving some communities with poorer access. Distributional analysis considers which populations gain and bear costs. Equity may justify explicit discussion of alternative values, priority weights or access measures, depending on the decision institution.

Include geographic, financial and social barriers, and engage affected people appropriately. CHEERS 2022 added attention to distributional effects and stakeholder participation. Counting all benefits into one total without describing who receives them can obscure a policy’s most important consequences.

17. Read public-health and prevention proposals critically

Back to contents

Prevention programmes can deliver benefits over long periods, sometimes outside a narrow health budget. Screening may improve outcomes under the right conditions but can also introduce false positives, unnecessary follow-up, anxiety and overdiagnosis. Vaccination, sanitation and chronic-disease services each involve different mechanisms and implementation requirements.

A useful evaluation compares actual alternatives, eligible populations, appropriate evidence and healthcare capacity. Do not assume every preventive intervention saves money; some improve health at additional cost and still warrant consideration. Distinguish the economic question from clinical recommendations, which require appropriate clinical and public-health expertise.

18. Make the evaluation reproducible and usable

Back to contents

Transparent reporting is a scientific duty. CHEERS 2022 supplies a twenty-eight-item reporting checklist for health economic evaluations and replaces its 2013 predecessor. It is a reporting guideline, not a scoring system for declaring a study valid. The updated NICE manual offers a jurisdiction-specific reference case, not a worldwide mandate.

Preserve the decision problem, model version, clinical sources, resource quantities, price year, calculation code, assumptions, stakeholder involvement and uncertainty results. Then explain what the evaluation can and cannot justify. Strong health economics helps real people make more informed choices under scarcity; it does not claim that one numerical score settles every clinical, political or ethical question.

Worked fictional case A: additional cost per additional QALY

Consider two invented programmes assessed on the same fictional patient population and from the same stated payer perspective. Programme A has expected cost of 20,000 illustrative currency units and delivers 5.0 discounted QALYs over the model horizon. Programme B has expected cost of 32,000 units and delivers 5.4 discounted QALYs. The incremental cost is 32,000 − 20,000 = 12,000; the incremental health gain is 5.4 − 5.0 = 0.4 QALYs. The ICER of B versus A is 12,000 ÷ 0.4 = 30,000 currency units per additional QALY.

This is arithmetic, not an approval decision. If an imaginary decision-maker valued one additional QALY at 40,000 currency units, the incremental net monetary benefit would be 40,000 × 0.4 − 12,000 = +4,000 units. That is a hypothetical threshold for a classroom example only. Real analyses need credible clinical evidence, discounting rules, competing alternatives, uncertainty and health-system values; they may reach a different conclusion.

Worked fictional case B: a favourable ICER does not pay the budget

An invented service identifies 500 eligible individuals in its first operating year. Planners expect 60% uptake and an added net expenditure of 2,500 currency units per treated person, measured against current practice for that year. Expected uptake is 500 × 0.60 = 300 people; estimated first-year incremental budget impact is 300 × 2,500 = 750,000 units. At 100% uptake and unchanged per-person spending, the comparable figure would be 1,250,000 units.

These estimates omit fixed start-up costs, staff constraints, possible price changes, offsetting downstream expenditure and any later-year uptake dynamics. They do not state how many QALYs the service generates. The budget question asks when and where financial resources are required; the cost-effectiveness question asks about incremental costs and health outcomes over the chosen horizon. Both analyses are necessary for many real decisions.

A practical audit before accepting a health economic claim

  • Confirm the decision problem, population and feasible alternatives.
  • Declare payer, health system, societal or other analytic perspective.
  • Check clinical effectiveness sources, follow-up and extrapolation.
  • Reconstruct resource quantities, unit values, price year and currency.
  • Verify QALY or other outcome method and any discounting.
  • Present incremental costs and effects before the ICER.
  • Keep budget impact, affordability and workforce limits visible.
  • Explore parameter and structural uncertainty and subgroup outcomes.
  • Describe equity trade-offs and stakeholder participation.
  • Use CHEERS for reporting completeness, not as a validity score.

Frequently asked questions about health economics

What is health economics?

It is the study of choices about scarce resources, incentives, financing, benefits and trade-offs within health and healthcare systems.

Is health economics just making healthcare cheaper?

No. It considers health improvement, quality, financial protection, access, efficiency and equity, not only expenditure reductions.

What is opportunity cost in healthcare?

It is the value of the best alternative use of resources forgone when one option is chosen.

Why do health insurers pool risk?

Pooling shares unpredictable financial costs across contributors and can protect people against large expenses.

What is a QALY?

A quality-adjusted life year is a health-outcome metric combining time lived and a defined health-related quality weight.

What is an ICER?

An incremental cost-effectiveness ratio divides added expected cost by added expected benefit relative to a stated comparator.

Can a negative ICER be read as automatically good?

No. It may represent different dominance situations; show changes in costs and benefits separately.

Does cost-effectiveness mean a programme is affordable?

No. Budget impact, capacity, cash flow and implementation can impose separate constraints.

Is NICE’s cost-effectiveness threshold universal?

No. NICE applies UK-specific methods, and policies or thresholds elsewhere may differ.

What is the difference between price and cost?

Price is what is charged or paid; economic cost is the value of resources used under a stated perspective.

What is CHEERS 2022?

It is a 28-item reporting guideline for health economic evaluations, not a certificate of scientific quality.

Can a model settle healthcare equity questions?

No. Distributional evidence helps reveal who benefits and bears burdens, but ethical and public decisions require broader deliberation.

Connect the economics, health, statistics and decision ecosystem

Economics explains scarcity and incentives; health sciences describe needs and outcomes; informatics establishes reliable data; biostatistics and epidemiology help estimate effects; decision theory and experimental design clarify uncertainty. Read across these fields according to the weakness in the current decision rather than treating health economics as a single formula.

Official sources and scope of the 2026 methods

Sources reviewed on 24 October 2026. NICE’s technology-appraisal methods cited here were updated on 31 March 2026 and apply within NICE’s own UK appraisal framework; they are not global thresholds or Singapore health-financing rules. CHEERS 2022 is a reporting guideline rather than a formal score of scientific quality, and its checklist is not a budget-impact analysis method. Every cost, QALY, population and threshold in the worked cases is fictional educational data. This article does not provide medical, reimbursement or legal advice.

Return to chapter index · The Gold Standard hub · How X Works hub